Depression Clinical Trials in Houston, TX

50 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD	Phase 3	Lipocine Inc.	<1 mi
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.	Phase 3	AbbVie	<1 mi
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	<1 mi
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms	Phase 3	Janssen Research & Development, LLC	<1 mi
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A	LivaNova	<1 mi
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression	N/A	The University of Texas Health Science Center, Houston	<1 mi
Improving Adult Protective Services Client Outcomes: A Stepped-Care Social and Mental Health Engagement Program	N/A	The University of Texas Health Science Center, Houston	<1 mi
Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes	—	M.D. Anderson Cancer Center	<1 mi
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression	N/A	VA Office of Research and Development	<1 mi
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response	Phase 2	ACADIA Pharmaceuticals Inc.	<1 mi
Neurobehavioral Therapy For Epilepsy And Major Depressive Disorder	N/A	The University of Texas Health Science Center, Houston	<1 mi
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder	Phase 3	Neumora Therapeutics, Inc.	<1 mi
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	<1 mi
Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression	N/A	The University of Texas Health Science Center, Houston	<1 mi
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)	N/A	Baylor College of Medicine	<1 mi
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression	Phase 1	The University of Texas Health Science Center, Houston	<1 mi
Transcutaneous Vagus Nerve Stimulation for Attention and Memory	N/A	Baylor College of Medicine	<1 mi
Improving Behavioral Health for Caregivers and Children After Pediatric Injury	N/A	Medical University of South Carolina	<1 mi
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users	N/A	Baylor College of Medicine	<1 mi
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia	N/A	GrayMatters Health Ltd.	<1 mi
Study to Assess the Safety and Effectiveness of NMRA-335140-501	Phase 3	Neumora Therapeutics, Inc.	<1 mi
DBS for Depression	N/A	Baylor College of Medicine	<1 mi
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality	Phase 2	The University of Texas Health Science Center, Houston	<1 mi
Telehealth Behavioral Activation for Teens	N/A	Baylor College of Medicine	<1 mi
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression	Phase 1	Baylor College of Medicine	<1 mi
Mapping and Modulating the Spatiotemporal Dynamics of Socio-Affective Processing	N/A	Baylor College of Medicine	<1 mi
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)	N/A	Abbott Medical Devices	<1 mi
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3	Intra-Cellular Therapies, Inc.	<1 mi
Deep Brain Stimulation of Treatment-Resistant Bipolar Depression	N/A	Wayne Goodman MD	<1 mi
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder	Phase 3	Cybin IRL Limited	<1 mi
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"	Phase 3	Cybin IRL Limited	<1 mi
Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)	N/A	Joao L. DeQuevedo	<1 mi
Intracranial Investigation of Neural Circuity Underlying Human Mood	N/A	Baylor College of Medicine	<1 mi
ALTO-100 in Bipolar Disorder With Depression (BD-D)	Phase 2	Alto Neuroscience	<1 mi
Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia	N/A	The University of Texas Health Science Center, Houston	<1 mi
Expansion and Evaluation of AI-generated Clinical Assessment (AI-COA®) of Depression and Anxiety Severity	N/A	Deliberate Solutions Inc.	<1 mi
Neonatal Neurodevelopmental Outcomes	—	Baylor College of Medicine	<1 mi
Physiological and Psychological Effects of Music Therapy in the Pregnant Woman and Fetus	N/A	Christina Chianis Reed	<1 mi
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer	Phase 2/3	M.D. Anderson Cancer Center	<1 mi
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	7 mi
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study	Phase 3	Yale University	7 mi
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder	Phase 2	AbbVie	7 mi
The OBSERVE Protocol	—	Yale University	7 mi
Study of ALTO-300 in MDD	Phase 2	Alto Neuroscience	14 mi
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder	Phase 2	Sirtsei Pharmaceuticals, Inc.	15 mi
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms	Phase 4	Axsome Therapeutics, Inc.	19 mi
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)	Phase 3	Xenon Pharmaceuticals Inc.	20 mi
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia	Phase 2	Syndeio Biosciences, Inc	20 mi
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	27 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.